Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/2992
Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray
Rafael R de Assis.
Aarti Jain.
Rie Nakajima.
Algis Jasinskas.
Jiin Felgner.
Joshua Miago Obiero.
Oluwasanmi Oladapo Adenaiye.
Sheldon Tai.
Filbert H Hong.
Philip Norris.
Mars Stone.
Graham Simmons.
Anil Bagri.
Martin Schreiber.
Andreas Buser.
Andreas Holbro.
Manuel Battegay.
Donald K Milton.
- Prometheus Study Group.
Huw Davies.
Laurence M Corash.
Michael P Busch.
Philip L Felgner.
Saahir Khan.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.04.15.043364
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates complete discrimination of these two groups. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.
www.biorxiv.org
2020
Artículo
https://www.biorxiv.org/content/10.1101/2020.04.15.043364v1.full.pdf
Inglés
VIRUS RESPIRATORIOS
Aparece en las colecciones: Artículos científicos

Cargar archivos:


Fichero Tamaño Formato  
1103117.pdf2.68 MBAdobe PDFVisualizar/Abrir